Idenix (IDIX) Up 45%, Achillion (ACHN) Up 15% On Inhibitex Takeover
Tweet
Share
E-mail
Get Alerts INHX Hot Sheet
Join SI Premium – FREE
Inhibitex (Nasdaq: INHX) peers are already seeing big upside in pre-open trading Monday following this weekend's big takeover by Bristol-Myers Squibb's (NYSE: BMY) at a 163% premium.
Idenix Pharmaceuticals (Nasdaq: IDIX) is up 45% and Achillion Pharmaceuticals (Nasdaq: ACHN) is up Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is already up 15%.
Bigger and more established Hep C player Vertex Pharmaceuticals (Nasdaq: VRTX) is up 3%.
Click here for more takeover targets in the broader biotech space.
Idenix Pharmaceuticals (Nasdaq: IDIX) is up 45% and Achillion Pharmaceuticals (Nasdaq: ACHN) is up Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is already up 15%.
Bigger and more established Hep C player Vertex Pharmaceuticals (Nasdaq: VRTX) is up 3%.
Click here for more takeover targets in the broader biotech space.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackstone (BX) Nears Deal to Sell Control of S.Korean Pharma Wholesaler Geo-young to MBK Parnters for Over $1B - Reuters
- Northrop Grumman (NOC) Working With Musk's SpaceX on US Spy Satellite System - Reuters
- UBS AG (UBS) Shuts Some China Private Funds, Will Lay Off Staff - Reuters
Create E-mail Alert Related Categories
Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
